JPI Healthcare, a medical imaging device specialist, is rapidly evolving into an artificial intelligence (AI)-driven digital imaging platform company, leveraging its world-leading X-ray grid technology. The firm is expanding beyond component supply to develop proprietary medical imaging systems, software, and next-generation convergence technologies, intensifying its global market strategy.
Industry sources reported on Monday that JPI Healthcare’s core competitive edge lies in its grid technology, a crucial component determining X-ray image quality. Grids function to eliminate scatter radiation during X-ray imaging, thereby enhancing image clarity.
The company has gained global recognition for commercializing carbon-based grids, a departure from the aluminum materials commonly used worldwide. Carbon grids can produce high-resolution images at lower radiation doses, giving them an edge in the high-end medical device market where precise diagnostics are essential.
Kim Kyung-woo, Executive Director of JPI Healthcare, recently told News1 that its decades of expertise in micro-processing and innovative material technology have cemented the global market leadership. It’s now transitioning from a component supplier to a provider of tailored imaging solutions.
JPI Healthcare is accelerating its expansion into AI-based software and imaging systems, moving beyond its traditional hardware focus. The company is bolstering its next-generation product line, including its proprietary digital tomosynthesis (DTS) device StriXion, mobile hybrid computed tomography (CT) DeteCT, and digital X-ray system DRE Duo.
The firm is implementing a dual-track strategy, nurturing both its stable original equipment manufacturer (OEM)-focused business and developing systems under its own brand. This approach aims to maintain its world-leading grid business as a reliable revenue stream while reinvesting in research and development (R&D) for next-generation medical imaging devices, creating a sustainable growth cycle.
JPI Healthcare is shifting its global market approach from simple exports to tailored local strategies.
The company is customizing its products to meet specific national medical regulations and clinical environments. It’s also expanding the use of automatic exposure control (AEC) and dose area product (DAP) technologies to precisely manage patient radiation exposure. The firm is actively pursuing the U.S. Food and Drug Administration (FDA) approval in the U.S. and addressing European market requirements.
Looking ahead, JPI Healthcare anticipates a rapid transformation of the medical imaging industry, driven by AI and advanced convergence technologies.
Executive Director Kim stated that the future of medical devices lies in a highly integrated industry, combining radiation physics and medicine with AI, robotics, and digital twins. A company’s competitiveness will hinge on its ability to foster collaboration among experts across these diverse fields.
He added that it aims to demonstrate how JPI Healthcare’s technology enhances image value across all applications. Its ultimate goal is to extend diagnostic imaging beyond diagnostics into treatment. They’re poised to grow into a digital imaging specialist, expanding the reach from healthcare to security and industrial imaging sectors.